Global Recombinant Human Follitropin Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08254752

Publication Date:

August 7, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Recombinant Human Follitropin market size will reach US$ 2072 million by 2031.
Follitropin is a form of recombinant human follicle stimulating hormone used to stimulate follicle development in women with primary ovarian hypogonadism and in men with hypogonadotropic hypogonadism.
Infertility affects many people at some point in their lives, according to a new report from the World Health Organization (WHO) released in 2023. About 17.5% of adults (about one in six people worldwide) experience infertility, highlighting the urgent need to expand access to affordable, high-quality reproductive health care for those who need it. Recombinant human follitropin is used in the treatment of female infertility and male hypogonadism. The safety and effectiveness of recombinant human follitropin have been verified in a large number of clinical applications. In the future, as biosimilar technology continues to mature and costs decrease, generic drugs will gradually break the market monopoly of original drugs and improve the accessibility of treatment. Generic drug companies will further enhance their market competitiveness by optimizing production processes, improving product quality and developing long-acting preparations.
The 鈥淩ecombinant Human Follitropin Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Follitropin sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Follitropin sales for 2025 through 2031. With Recombinant Human Follitropin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Follitropin industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Follitropin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Human Follitropin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Follitropin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Follitropin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Follitropin.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Follitropin market by product type, application, key players and key regions and countries.
Segmentation by Type:
75IU
150IU
300IU
Others
Segmentation by Application:
Women
Men
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
Organon
骋别诲别辞苍听搁颈肠丑迟别谤
Ferring
Changchun High-Tech
Theramex
Qilu Pharmaceutical

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Human Follitropin Market Size (2020-2031)
2.1.2 Recombinant Human Follitropin Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Recombinant Human Follitropin by Country/Region (2020, 2024 & 2031)
2.2 Recombinant Human Follitropin Segment by Type
2.2.1 75IU
2.2.2 150IU
2.2.3 300IU
2.2.4 Others
2.3 Recombinant Human Follitropin Market Size by Type
2.3.1 Recombinant Human Follitropin Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Recombinant Human Follitropin Market Size Market Share by Type (2020-2025)
2.4 Recombinant Human Follitropin Segment by Application
2.4.1 Women
2.4.2 Men
2.5 Recombinant Human Follitropin Market Size by Application
2.5.1 Recombinant Human Follitropin Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Recombinant Human Follitropin Market Size Market Share by Application (2020-2025)
3 Recombinant Human Follitropin Market Size by Player
3.1 Recombinant Human Follitropin Market Size Market Share by Player
3.1.1 Global Recombinant Human Follitropin Revenue by Player (2020-2025)
3.1.2 Global Recombinant Human Follitropin Revenue Market Share by Player (2020-2025)
3.2 Global Recombinant Human Follitropin Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Recombinant Human Follitropin by Region
4.1 Recombinant Human Follitropin Market Size by Region (2020-2025)
4.2 Global Recombinant Human Follitropin Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Human Follitropin Market Size Growth (2020-2025)
4.4 APAC Recombinant Human Follitropin Market Size Growth (2020-2025)
4.5 Europe Recombinant Human Follitropin Market Size Growth (2020-2025)
4.6 Middle East & Africa Recombinant Human Follitropin Market Size Growth (2020-2025)
5 Americas
5.1 Americas Recombinant Human Follitropin Market Size by Country (2020-2025)
5.2 Americas Recombinant Human Follitropin Market Size by Type (2020-2025)
5.3 Americas Recombinant Human Follitropin Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Follitropin Market Size by Region (2020-2025)
6.2 APAC Recombinant Human Follitropin Market Size by Type (2020-2025)
6.3 APAC Recombinant Human Follitropin Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Recombinant Human Follitropin Market Size by Country (2020-2025)
7.2 Europe Recombinant Human Follitropin Market Size by Type (2020-2025)
7.3 Europe Recombinant Human Follitropin Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Follitropin by Region (2020-2025)
8.2 Middle East & Africa Recombinant Human Follitropin Market Size by Type (2020-2025)
8.3 Middle East & Africa Recombinant Human Follitropin Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Recombinant Human Follitropin Market Forecast
10.1 Global Recombinant Human Follitropin Forecast by Region (2026-2031)
10.1.1 Global Recombinant Human Follitropin Forecast by Region (2026-2031)
10.1.2 Americas Recombinant Human Follitropin Forecast
10.1.3 APAC Recombinant Human Follitropin Forecast
10.1.4 Europe Recombinant Human Follitropin Forecast
10.1.5 Middle East & Africa Recombinant Human Follitropin Forecast
10.2 Americas Recombinant Human Follitropin Forecast by Country (2026-2031)
10.2.1 United States Market Recombinant Human Follitropin Forecast
10.2.2 Canada Market Recombinant Human Follitropin Forecast
10.2.3 Mexico Market Recombinant Human Follitropin Forecast
10.2.4 Brazil Market Recombinant Human Follitropin Forecast
10.3 APAC Recombinant Human Follitropin Forecast by Region (2026-2031)
10.3.1 China Recombinant Human Follitropin Market Forecast
10.3.2 Japan Market Recombinant Human Follitropin Forecast
10.3.3 Korea Market Recombinant Human Follitropin Forecast
10.3.4 Southeast Asia Market Recombinant Human Follitropin Forecast
10.3.5 India Market Recombinant Human Follitropin Forecast
10.3.6 Australia Market Recombinant Human Follitropin Forecast
10.4 Europe Recombinant Human Follitropin Forecast by Country (2026-2031)
10.4.1 Germany Market Recombinant Human Follitropin Forecast
10.4.2 France Market Recombinant Human Follitropin Forecast
10.4.3 UK Market Recombinant Human Follitropin Forecast
10.4.4 Italy Market Recombinant Human Follitropin Forecast
10.4.5 Russia Market Recombinant Human Follitropin Forecast
10.5 Middle East & Africa Recombinant Human Follitropin Forecast by Region (2026-2031)
10.5.1 Egypt Market Recombinant Human Follitropin Forecast
10.5.2 South Africa Market Recombinant Human Follitropin Forecast
10.5.3 Israel Market Recombinant Human Follitropin Forecast
10.5.4 Turkey Market Recombinant Human Follitropin Forecast
10.6 Global Recombinant Human Follitropin Forecast by Type (2026-2031)
10.7 Global Recombinant Human Follitropin Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Recombinant Human Follitropin Forecast
11 Key Players Analysis
11.1 Merck KGaA
11.1.1 Merck KGaA Company Information
11.1.2 Merck KGaA Recombinant Human Follitropin Product Offered
11.1.3 Merck KGaA Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Merck KGaA Main Business Overview
11.1.5 Merck KGaA Latest Developments
11.2 Organon
11.2.1 Organon Company Information
11.2.2 Organon Recombinant Human Follitropin Product Offered
11.2.3 Organon Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Organon Main Business Overview
11.2.5 Organon Latest Developments
11.3 骋别诲别辞苍听搁颈肠丑迟别谤
11.3.1 骋别诲别辞苍听搁颈肠丑迟别谤 Company Information
11.3.2 骋别诲别辞苍听搁颈肠丑迟别谤 Recombinant Human Follitropin Product Offered
11.3.3 骋别诲别辞苍听搁颈肠丑迟别谤 Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 骋别诲别辞苍听搁颈肠丑迟别谤 Main Business Overview
11.3.5 骋别诲别辞苍听搁颈肠丑迟别谤 Latest Developments
11.4 Ferring
11.4.1 Ferring Company Information
11.4.2 Ferring Recombinant Human Follitropin Product Offered
11.4.3 Ferring Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Ferring Main Business Overview
11.4.5 Ferring Latest Developments
11.5 Changchun High-Tech
11.5.1 Changchun High-Tech Company Information
11.5.2 Changchun High-Tech Recombinant Human Follitropin Product Offered
11.5.3 Changchun High-Tech Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Changchun High-Tech Main Business Overview
11.5.5 Changchun High-Tech Latest Developments
11.6 Theramex
11.6.1 Theramex Company Information
11.6.2 Theramex Recombinant Human Follitropin Product Offered
11.6.3 Theramex Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Theramex Main Business Overview
11.6.5 Theramex Latest Developments
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Information
11.7.2 Qilu Pharmaceutical Recombinant Human Follitropin Product Offered
11.7.3 Qilu Pharmaceutical Recombinant Human Follitropin Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Qilu Pharmaceutical Main Business Overview
11.7.5 Qilu Pharmaceutical Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂